botensilimab

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

botensilimab
Sep 14, 2024, 09:43 | Insight
Article of the day, September 14th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Sep 10, 2024, 13:38 | Insight
Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24
Agenus shared on LinkedIn: “The Agenus team is headed to Barcelona for ESMO24. This Friday,…
Sep 4, 2024, 11:47 | Dialogues
Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024
In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the…
Aug 10, 2024, 13:39 | Insight
Botensilimab’s effectiveness against tumours poorly responsive to conventional immunotherapy
Justin Stebbing shared a post on LinkedIn:  “Congratulations to Dhan Chand and the Agenus team…
Aug 10, 2024, 11:58 | Insight
Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…
Aug 9, 2024, 07:16 | Blog
Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers
Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and…
Jul 29, 2024, 06:38 | Blog
Heart of a Warrior: Jennifer’s Triumphant Fight Against Cancer
Jennifer's story is a testament to strength and resilience. Faced with limited treatment options, she…
Jul 19, 2024, 02:00 | Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 13, 2024, 09:41 | Insight
IMMONC - Immune Oncology Research Institute's Experience in Advancing Clinical Cancer Research in Armenia
Cancer affects people across the world regardless of their socioeconomic status. However, low- and middle-income…
Jul 8, 2024, 12:29 | Drugs
Jennifer Buell: NCI Announces Availability of Botensilimab for Clinical Development
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X: “NCI Announces…
Jul 5, 2024, 15:53 | Drugs
Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial
Gevorg Tamamyan posted on LinkedIn: "Just saw the presentation from ESMO GI Annual Congress and the…
Jul 1, 2024, 16:15 | Blog
We need to hurry up, because cancer and patients cannot wait!
Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on…
Jun 30, 2024, 04:58 | Blog
Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC
Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn:  .…
Jun 29, 2024, 11:05 | Societies
Neoadjuvant botensilimab and balstilimab in colorectal cancer
Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X: "Neoadjuvant botensilimab (1 dose)…
Jun 28, 2024, 15:58 | Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 | Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 13:41 | Insight
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Agenus shared on their X page: "New data from the NEST clinical trial was presented…
Jun 28, 2024, 13:09 | Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 13:00 | Insight
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…
Jun 17, 2024, 11:39 | Insight
Bot/bal in relapsed refractory MSS metastatic colorectal cancer - a quick summary
Arndt Vogel shared a post on X: "Botensilimab plus balstilimab in relapsed/refractory MSS mCRC. Phase…
Jun 15, 2024, 02:09 | Insight
Anthony El-Khoueiry: Botensilimab with expansion in MSS CRC; activity noted across multiple cold tumors
Anthony El-Khoueiry, Associate Professor of Medicine at University of Southern California Norris Comprehensive Cancer Center,…
Jun 14, 2024, 01:23 | Insight
New Paper Alert! Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab
Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab Authors: Andrea J. Bullock,…
Jun 13, 2024, 23:58 | Insight
Steven O'Day shared the latest data and insights from our botensilimab programs - Agenus
Agenus shared on LinkedIn: "Yesterday, our Chief Medical Officer, Dr. Steven O'Day, joined clinical experts…
Jun 13, 2024, 17:33 | Insight
Agenus' Phase 1 clinical trial results have been published in Nature
Agenus shared their publication on investigational immunotherapeutic agents in Nature: "Results from our Phase 1…
Jun 10, 2024, 16:17 | Blog
Steven O’Day will be presenting an update on botensilimab programs at Nature Conferences’s event - Agenus
Quoting Agenus on X: "Tomorrow, Dr. Steven O’Day will be speaking at Nature Conferences’ Cancer Immunotherapy…
May 17, 2024, 11:18 | Drugs
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Agenus shared on LinkedIn: “Today we announced that Agenus has been granted a Type B…
May 16, 2024, 16:51 | Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
May 12, 2024, 03:08 | Blog
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…
Apr 28, 2024, 05:36 | Societies
Agenus selected for a poster presentation at the American Society of Clinical Oncology's ASCO2024 Annual Meeting
Quoting Agenus's post on LinkedIn: "Mark your calendars! We have been selected for a poster…
Apr 13, 2024, 06:43 | Opinion
Agenus announced updated Phase 1 data and progress botensilimab/balstilimab combination in metastatic MSS colorectal cancer
Agenus shared on LinkedIn: "Today we announced updated Phase 1 data and progress on our investigational…
Mar 26, 2024, 15:02 | Insight
Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks
Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn: "We…
Feb 21, 2024, 12:05 | Insight
Pashtoon Kasi: See the discussion on our NEST-1trial by Rachna Shroff and Shaalan Beg
Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…
Feb 14, 2024, 14:59 | Blog
Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL
Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…
Feb 14, 2024, 13:40 | Insight
Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer
Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…
Jan 31, 2024, 14:14 | Blog
Elad Sharon: The hottest new ICI BOTENSILIMAB in Kidney Cancer
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Michael Serzan, Genitourinary…
Jan 28, 2024, 16:11 | Drugs
Michael Serzan: About the hottest new ICI BOTENSILIMAB in Kidney Cancer?
Michael Serzan, Genitourinary Medical Oncologist from Dana-Farber Cancer Institute, shared on X: " Interested in…
Jan 27, 2024, 15:39 | Blog
Agenus joined oncology leaders from across the globe at ASCO GI (GI24)
Agenus recently posted on their LinkedIn page: "Agenus joined oncology leaders from across the globe…
Jan 20, 2024, 14:14 | Drugs
Pashtoon Kasi: Are we on the verge of a new drug combo for colon or rectal cancer?
Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X: "🆕🗞️Just…
Dec 20, 2023, 09:57 | Blog
Pashtoon Kasi: Our paper with more than 10,000 accesses ranks at N1 in Oncogene Journal
Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X:…
Nov 3, 2023, 12:10 | Drugs
Steven O'Day shared their recent webinar presented by Endpoints News on “The Next I-O Revolution”
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: ''Did you catch our…
Oct 24, 2023, 14:05 | Drugs
Agenus is proud to unveil the latest research from our investigational botensilimab programs - Agenus
Agenus shared a post on LinkedIn: "Agenus is proud to unveil the latest research from…
Oct 23, 2023, 15:23 | Drugs
Pashtoon Kasi: So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:…
Oct 23, 2023, 13:31 | Drugs
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…
Oct 15, 2023, 19:05 | Blog
Steven O'Day: I am thrilled to be joining Dr. Benjamin Schlechter, Dr. Pashtoon Kasi, and Phuong Ly-Gallagher for an engaging discussion on “The Next I-O Revolution”.
Sep 25, 2023, 16:07 | Insight
Steven O'Day: Today is World Cancer Research Day, which is a good day for me to share three things.
Quoting Steven O'Day, the Chief Medical Officer at Agenus, on LinkedIn: "Today is World Cancer…
Sep 24, 2023, 18:03 | Blog
Pashtoon Murtaza Kasi: The imagery at RareCyte Incorporated will blow your mind.
Quoting Pashtoon Murtaza Kasi, Oncologist and Researcher at Weill Cornel Medicine and New York- Presbyterian…
Sep 21, 2023, 11:16 | Drugs
Pashtoon Kasi: Are we on the verge of a new drug combo for colorectal cancer?
Pashtoon Kasi, the Director of Colon Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…
Jul 1, 2023, 06:00 | Drugs
Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer
In a post by Agenus on Linkedin, it says, "ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab…
All: 49 Posts: 1 - 100
Special Coverage